Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Next Previous
Trial Profile

A phase I/II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Carcinoid tumour; Gastro-enteropancreatic neuroendocrine tumour; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Feb 2019 According to an Advanced Accelerator Applications media release, based on results of this trial and phase III pivotal trial (NETTER-1), the Health Canada has approved Lutathera (lutetium (177Lu) oxodotreotide) for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with progressive disease.
  • 01 Feb 2018 According to an Advanced Accelerator Applications media release, Advanced Accelerator Applications is acquired by Novartis
  • 26 Jan 2018 According to a Food and drug administration media release, based on results from this and NETTER-1 trials the U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top